Tenaya Therapeutics, Inc. (TNYA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion.
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 11,346 | $8,386 | $8,261.02 | -$124.98 | -1.49% |
 Jonathan J. Marshall Spectrum Investment Advisors Inc. | 14,048 | $10,383 | $10,326.68 | -$56.32 | -0.54% |
 Dinan Hu R Squared Ltd | 31,503 | $22,761.12 | $23,312.22 | $551.1 | 2.42% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 5,000 | $3,675 | $3,640 | -$35 | -0.95% |
 Regan O'Neill Burkehill Global Management LP | 2M | $1.42M | $1.46M | $32,999.98 | 2.32% |
Tenaya Therapeutics, Inc. (TNYA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tenaya Therapeutics, Inc. ever had a stock split?
Tenaya Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Faraz Ali CEO | NASDAQ (NGS) Exchange | 87990A106 CUSIP |
| US Country | 70 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
Tenaya Therapeutics, Inc. is a pioneering biotechnology company based in the United States, dedicated to the discovery, development, and delivery of innovative therapies for heart disease. Utilizing advanced platforms in cellular regeneration, gene therapy, and precision medicine, Tenaya aims to transform the treatment landscape for patients suffering from various heart conditions. Since its establishment in 2016, the company has positioned itself at the forefront of cardiological research and therapy development, operating from its headquarters in South San Francisco, California.
Products and Services
- TN-201: An adeno-associated virus (AAV)-based gene therapy aimed at treating genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the MYBPC3 gene. This therapy is designed to address the genetic root of gHCM by providing a normal copy of the MYBPC3 gene to restore cardiac function.
- TN-301: A small molecule that inhibits histone deacetylase 6 (HDAC6), intended for use in patients with heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). By targeting HDAC6, TN-301 seeks to alleviate the symptoms and progression of these complex heart diseases.
- TN-401: Another AAV-based gene therapy developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by mutations in the plakophilin 2 (PKP2) gene. This innovative approach aims to correct the underlying genetic abnormality, potentially providing a durable treatment option for those affected by gARVC.
- AAV-based gene therapy for DCM: Focused on delivering the dwarf open reading frame (DWORF) gene directly to the heart, this therapy is being developed for dilated cardiomyopathy (DCM). The DWORF gene plays a crucial role in cardiac muscle function, and its delivery could help in restoring heart muscle function in DCM patients.
- Reprogramming program: A cutting-edge AAV-based approach aimed at cardiac regeneration. This program is designed to replace heart cells lost due to myocardial infarction, offering new hope for heart failure patients. By reprogramming cells within the heart, this strategy could revolutionize the treatment of heart failure, providing a novel avenue for cardiac repair and regeneration.
